严重肢体缺血治疗市场 - 增长、趋势、COVID-19 影响和预测(2022 - 2027 年)

市场按治疗类型(设备、药物和手术)和地理划分。

市场快照

Critical Limb Ischemia Treatment Market
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 8.3 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

市场概况

研究的严重肢体缺血治疗市场预计在预测期内以近 8.3% 的复合年增长率增长。导致市场增长的主要因素是严重肢体缺血的患病率增加。导致严重肢体缺血疾病的关键因素是老年人口的增加,他们更容易患上这些疾病,其他因素包括糖尿病、肥胖、久坐不动的生活方式、吸烟和血压升高。未经治疗的严重肢体缺血可导致特定肢体截肢。预计严重肢体缺血发病率的增加将推动对其治疗的需求,这也将推动全球严重肢体缺血治疗市场的增长。此外,医疗器械和制药公司对研发项目的投资不断增加,正在推动市场增长。然而,药品故障和药品召回是市场增长的主要障碍。

报告范围

根据报告的范围,严重肢体缺血是一种外周动脉慢性疾病,其中与动脉粥样硬化相关的慢性炎症导致腿部、手和脚的血液和氧气流动缩短。该报告按治疗类型和地理位置细分。

By Treatment Type
Devices
Embolic Protection Devices
Peripheral Dilatation Systems
Medications
Antiplatelet Drugs
Antihypertensive Agents
Lipid-lowering Agents
Others
Surgery
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

主要市场趋势

药物部门预计将在预测期内以更快的速度增长

  • 严重肢体缺血治疗市场的药物部分包括抗高血压药、抗血小板药、抗血栓药、降脂药等。
  • 对于不能灵活进行手术或血管内血运重建的严重肢体缺血患者或血运重建尝试无效的患者,药物是减轻疼痛和治疗患者的唯一方法。几项研究表明,药物可以减少缺血性静息痛、溃疡大小和截肢需要。
  • 随着老年人口的增加,患者数量也增加,这反过来又促进了市场增长。
Age above 60

北美在市场上占主导地位,预计在预测期内也会如此

在整个预测期内,预计北美将主导整个严重肢体缺血 (CIL) 治疗市场。市场增长是由于关键参与者的存在、该地区 CIL 患者的高患病率、成熟的医疗保健基础设施以及品牌药物的可用性等因素,这些因素是其在市场上占有很大份额的一些关键因素。此外,有益的政府举措和研究合作伙伴数量的增加是预计增加市场增长的一些驱动因素。美国拥有最大的市场份额。美国在发达国家中拥有独特的医疗保健体系。但是,该国的医院成本非常高;政府或私人保险承保。

Autoimmune Treatment

竞争格局

严重肢体缺血治疗市场竞争适度,由几个主要参与者组成。目前主导市场的一些公司是 Medtronic plc、Abbott Laboratories、Rexgenero Ltd.、LimFlow SA、Cardiovascular Systems, Inc. 和 ThermoGenesis Holdings, Inc.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increase in prevalence of Critical Limb Ischemia

      2. 4.2.2 Improvement in health care infrastructure

    3. 4.3 Market Restraints

      1. 4.3.1 Drug Failure and Drug Recalls

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Treatment Type

      1. 5.1.1 Devices

        1. 5.1.1.1 Embolic Protection Devices

        2. 5.1.1.2 Peripheral Dilatation Systems

      2. 5.1.2 Medications

        1. 5.1.2.1 Antiplatelet Drugs

        2. 5.1.2.2 Antihypertensive Agents

        3. 5.1.2.3 Lipid-lowering Agents

        4. 5.1.2.4 Others

      3. 5.1.3 Surgery

    2. 5.2 Geography

      1. 5.2.1 North America

        1. 5.2.1.1 United States

        2. 5.2.1.2 Canada

        3. 5.2.1.3 Mexico

      2. 5.2.2 Europe

        1. 5.2.2.1 Germany

        2. 5.2.2.2 United Kingdom

        3. 5.2.2.3 France

        4. 5.2.2.4 Italy

        5. 5.2.2.5 Spain

        6. 5.2.2.6 Rest of Europe

      3. 5.2.3 Asia-Pacific

        1. 5.2.3.1 China

        2. 5.2.3.2 Japan

        3. 5.2.3.3 India

        4. 5.2.3.4 Australia

        5. 5.2.3.5 South Korea

        6. 5.2.3.6 Rest of Asia-Pacific

      4. 5.2.4 Middle East and Africa

        1. 5.2.4.1 GCC

        2. 5.2.4.2 South Africa

        3. 5.2.4.3 Rest of Middle East and Africa

      5. 5.2.5 South America

        1. 5.2.5.1 Brazil

        2. 5.2.5.2 Argentina

        3. 5.2.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Medtronic plc

      2. 6.1.2 LimFlow SA

      3. 6.1.3 Cynata Therapeutics Ltd

      4. 6.1.4 Cardiovascular Systems, Inc.

      5. 6.1.5 Eli Lilly and Company

      6. 6.1.6 Abbott Laboratories

      7. 6.1.7 Rexgenero Ltd.

      8. 6.1.8 ThermoGenesis Holdings, Inc

      9. 6.1.9 Teva Pharmaceuticals

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Critical Limb Ischemia Treatment Market market is studied from 2018 - 2026.

The Critical Limb Ischemia Treatment Market is growing at a CAGR of 8.3% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Medtronic plc, LimFlow SA, Cardiovascular Systems, Inc, Eli Lilly and Company, Abbott Laboratories are the major companies operating in Critical Limb Ischemia Treatment Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!